Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 in Patients With Mature B-cell Malignancies

Next Previous
Trial Profile

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ICP-248 in Patients With Mature B-cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesutoclax (Primary)
  • Indications Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors InnoCare Pharma

Most Recent Events

  • 02 Jun 2025 Preliminary safety and efficacy results (n=68) presented in the InnoCare Pharma media release.
  • 02 Jun 2025 According to an InnoCare Pharma media release, company presented preliminary safety and efficacy data from this study at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 04 Feb 2025 Planned number of patients changed from 105 to 191.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top